AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...
AbbVie (ABBV) announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody ...
AbbVie (ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose ...
Netflix France’s boxing drama has been making waves on Netflix around the globe since its debut on November 8th, 2024, with the streamer confirming that the show created by Franck Gastambide and ...